Application of guaiacol in treatment of rheumatoid arthritis

By preparing guaiacol as an intraperitoneal injection for the treatment of rheumatoid arthritis, the shortcomings of existing treatment methods have been overcome, achieving effective treatment of rheumatoid arthritis with significant anti-inflammatory and repair effects.

CN121926906APending Publication Date: 2026-04-28GUANGXI UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610041268.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-13
Publication Date
2026-04-28

AI Technical Summary

Technical Problem

Current treatments for rheumatoid arthritis suffer from problems such as insufficient or ineffective response in some patients, significant side effects from long-term medication, high cost of biologics and difficulty in achieving immune tolerance reconstruction, and a lack of reports on the effective use of guaiacol.

Method used

Using guaiacol as the active ingredient, an intraperitoneal injection for the treatment of rheumatoid arthritis was prepared.

Benefits of technology

Guaiacin significantly downregulates the expression of macrophage inflammatory factors, relieves arthritis symptoms, improves cartilage damage, inhibits osteoclast formation, and reduces the level of pro-inflammatory factors, demonstrating significant therapeutic effects without obvious side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121926906A_ABST
    Figure CN121926906A_ABST
Patent Text Reader

Abstract

The invention discloses application of guaiacol in treatment of rheumatoid arthritis, and particularly relates to application of guaiacol in preparation of drugs for treating rheumatoid arthritis. Cell experiments prove that guaiacol can effectively down-regulate expression of proinflammatory factors in macrophages and up-regulate expression of anti-inflammatory factors, and has remarkable anti-inflammatory activity; animal experiments show that the guaiacol effectively relieves rheumatoid arthritis model mouse diseases, and the specific manifestation is that the guaiacol obviously relieves the mouse claw swelling degree, reduces the arthritis disease score, obviously improves joint inflammatory cell infiltration, repairs cartilage injury, inhibits osteoclast generation and reduces the number of joint apoptotic cells; meanwhile, the level of proinflammatory factors in serum of mice can be effectively reduced, and the level of proinflammatory repair factors can be up-regulated. The invention proves that guaiacol has a definite curative effect on rheumatoid arthritis, good biological safety and no obvious side effect, provides a new effective active component for the treatment of rheumatoid arthritis, and has a good prospect of being developed into the medicine for treating rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical applications of guaiacol, and particularly relates to the application of guaiacol in the treatment of rheumatoid arthritis. Background Technology

[0002] Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by inflammatory proliferation of the synovial tissue, progressive destruction of articular cartilage and bone, ultimately leading to joint deformities, functional impairment, and systemic complications. The global prevalence of this disease is approximately 0.5%-1%, with a higher incidence in women than men. Its pathogenesis involves a complex interplay of multiple factors, including genetics, environmental factors, and abnormal activation of the immune system.

[0003] Currently, clinical treatment of rheumatoid arthritis (RA) mainly revolves around controlling inflammation, relieving symptoms, delaying joint damage, and improving quality of life. Traditional treatment regimens include nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs, such as methotrexate). With the application of biologics (such as anti-TNF-α monoclonal antibodies and IL-6 receptor antagonists) and targeted synthetic DMARDs (such as JAK inhibitors), the condition of some patients has improved significantly. However, current treatments still face many challenges: some patients do not respond well to or are ineffective with existing drugs (refractory RA); long-term use may cause adverse reactions such as infection and liver and kidney damage; biologics are expensive and require injection; and current methods are insufficient to achieve immune tolerance reconstruction or disease cure.

[0004] Guaiacol (o-methoxy-phenol, also known as o-methoxyphenol) is an aromatic compound found in various plants and is one of the active ingredients in turmeric, a traditional Chinese medicine with anti-inflammatory properties. Previous studies have shown that guaiacol can directly inhibit the expression of COX-2 (cyclooxygenase-2) and the activation of the NF-κB pathway. In inflammatory responses, NF-κB acts as a "master switch" regulating the expression of various inflammatory factors, while COX-2 is a key enzyme in the synthesis of prostaglandins (such as PGE2) that cause pain and fever; therefore, guaiacol possesses excellent anti-inflammatory potential.

[0005] Currently, there are no reports in domestic or international research on the use of guaiacol for the treatment of rheumatoid arthritis. Summary of the Invention

[0006] The technical problem solved by this invention is to provide the application of guaiacol in the treatment of rheumatoid arthritis.

[0007] To solve the above-mentioned technical problems, the present invention adopts the following technical solution:

[0008] Application of guaiacol in the preparation of drugs for the treatment of rheumatoid arthritis.

[0009] The active ingredient in some rheumatoid arthritis treatments includes guaiacol.

[0010] The aforementioned medications for treating rheumatoid arthritis are injectable forms.

[0011] The injection is an intraperitoneal injection solution.

[0012] In the process of in-depth research on the medicinal uses of guaiacol, the inventors discovered that this drug has significant effects in the treatment of rheumatoid arthritis. Cellular experiments showed that guaiacol can effectively downregulate the expression of inflammatory factors in macrophages; animal experiments showed that guaiacol can effectively alleviate symptoms in mice with rheumatoid arthritis, specifically by: effectively reducing paw swelling, lowering arthritis disease scores, significantly improving inflammatory cell infiltration at the joints, repairing cartilage damage, inhibiting osteoclast formation, reducing the number of apoptotic cells at the joints, and effectively downregulating the levels of pro-inflammatory factors and upregulating the levels of pro-inflammatory repair factors in mouse serum. In conclusion, guaiacol has a definite therapeutic effect on rheumatoid arthritis with no obvious side effects, and shows great promise for development into a drug for treating rheumatoid arthritis. Attached Figure Description

[0013] Figure 1 This is a graph showing the detection results of mRNA expression levels of macrophage inflammation-related factors in an example of the present invention;

[0014] Figure 2 This is a schematic diagram of the treatment progress in a mouse model of rheumatoid arthritis in an example of the present invention;

[0015] Figure 3 This is a diagram illustrating the changes in the degree of paw swelling in each group of mice in this invention example;

[0016] Figure 4 This is a graph showing the statistical results of the changes in the degree of paw swelling in each group of mice in the examples of this invention;

[0017] Figure 5 These are Micro-CT images of mice in each group in the examples of this invention;

[0018] Figure 6 This is a graph showing the statistical results of disease scores for each group of mice in the examples of this invention;

[0019] Figure 7 This is a graph showing the statistical results of weight changes in each group of mice in the examples of this invention;

[0020] Figure 8 These are images showing the staining results of joint pathological sections of mice in each group in the examples of this invention.

[0021] Figure 9The images show the TUNEL staining results of joint sections from mice in each group in this invention example.

[0022] Figure 10 This is a statistical chart showing the ELISA detection results of inflammation-related factors in the serum of mice in each group in the examples of this invention;

[0023] Figure 11 The images show the H&E staining results of the five internal organs sections of mice in each group in the examples of this invention. Detailed Implementation

[0024] I. Experimental Materials

[0025] 1. Main experimental reagents and drugs: guaiacol, methotrexate, bovine type II collagen, Freund's complete adjuvant, Freund's incomplete adjuvant.

[0026] 2. Cells and Animals: Primary macrophages derived from mouse bone marrow, DBA / 1J mice, and C57BL / 6 mice.

[0027] II. Experimental Methods

[0028] 1. Extraction of mouse bone marrow-derived macrophages (BMDM)

[0029] Male C57BL / 6 mice aged 6-8 weeks were euthanized with carbon dioxide. The hind leg bones were harvested, and after removing the surface muscle, they were soaked in 75% ethanol. In a laminar flow hood, a sufficient amount of serum-free culture medium was drawn up using a 5 mL syringe. After cutting off both ends of the leg bone, the syringe needle was inserted into the bone cavity, and the bone marrow was flushed out using the culture medium. The marrow was collected in a centrifuge tube and centrifuged at 1400 rpm for 5 minutes. The precipitate was resuspended in complete culture medium containing M-CSF (20 ng / mL) and transferred to a 10 cm³ container. 2 Cultured in petri dishes; after three days, BMDM was digested with trypsin at a concentration of 5 × 10⁻⁶. 5 The concentration of cells in each well is determined by seeding cells into a six-well plate for later use.

[0030] 2. Detection of the anti-inflammatory effect of guaiacol on BMDM

[0031] Guaiacol was dissolved in phosphate buffered saline (PBS) to prepare a stock solution. Guaiacol solution was added to BMDM at a final concentration of 1 μM and incubated for 18 hours. Discard the cell supernatant, wash twice with PBS, add 500 μL of trizol to each well to lyse cells, and collect in 1.5 mL EP tubes; add chloroform at a 5:1 ratio, vortex vigorously for 30 seconds, and let stand for 10 minutes; centrifuge at 12000 rpm, 4℃ for 15 minutes, aspirate the supernatant to another EP tube, add an equal volume of isopropanol, gently invert to mix, and let stand for 10 minutes; centrifuge at 12000 rpm, 4℃ for 10 minutes; discard the supernatant, resuspend in 75% ethanol prepared with DEPC water, centrifuge at 7500 rpm, 4℃ for 10 minutes; repeat this step once; centrifuge at 12000 rpm, 4℃ for 5 minutes, aspirate the residual liquid, and air dry on ice; add 20-50 μL of DEPC water to dissolve RNA, detect RNA concentration using Nanodrop and adjust to 1 μg / μL. After reverse transcription of the extracted RNA, the expression levels of inflammation-related factors in BMDM of different treatment groups were detected by q-PCR.

[0032] 3. Establishment of a mouse model of rheumatoid arthritis

[0033] Insert the stirring rod of a hand-held homogenizer under the surface of the bovine type II collagen solution (2 mg / mL), and add an equal volume of Freund's complete adjuvant dropwise while stirring. Stir for 5 minutes, then pause for 2 minutes, until the mixture becomes a creamy consistency that does not drip. This is the initial immunization modeling solution. Administer the modeling solution subcutaneously via the tail to 6-8 week old male DBA-1J mice at a dose of 200 μL / mouse. 21 days after the initial immunization, administer a booster immunization modeling solution prepared from bovine type II collagen solution emulsified with Freund's incomplete adjuvant subcutaneously to the same mice using the same method and dose. When significant swelling of the paws and joints is observed, the mice are evenly divided into 4 groups based on disease scores for subsequent experiments.

[0034] 4. Treatment of rheumatoid arthritis in mice

[0035] Guaiacin and methotrexate were dissolved in PBS to prepare corresponding drug solutions. The experimental groups were: normal group (Ctrl), model group (Model), guaiacin group (GUA, 125 mg / kg), and methotrexate group (MTX, 1 mg / kg). Mice were administered the drug solution or PBS via intraperitoneal injection at a dose of 100 μL per mouse, once every two days. Mouse weight, paw thickness, and disease score were measured and recorded every two days. After two weeks of treatment, mice were anesthetized, and their paws were photographed using Micro-CT. Blood was collected via orbital sampling before euthanasia. After being left at room temperature for 60 minutes, the blood was centrifuged at 3000 g for 10 minutes at 4°C. The supernatant was collected and stored at -80°C for subsequent ELISA detection. Simultaneously, mouse paws and internal organs were collected, fixed in 4% paraformaldehyde, and used for subsequent section staining.

[0036] III. Experimental Results

[0037] 1. For example Figure 1 As shown, guaiacol has a significant anti-inflammatory effect on macrophages: after treatment with guaiacol, the mRNA expression levels of pro-inflammatory factors TNF-α and IL6 were significantly downregulated, while the mRNA expression level of anti-inflammatory factor TGF-β was significantly upregulated.

[0038] 2. For example Figures 2 to 10 As shown, guaiacol can effectively treat rheumatoid arthritis: compared with the normal group, the model group mice showed significant swelling of the paws and joints, accompanied by weight loss; joint section staining showed significant cartilage damage, inflammatory cell infiltration, and massive osteoclast proliferation, with a large number of apoptotic cells; serum pro-inflammatory factor levels were significantly increased, while anti-inflammatory factor levels were significantly decreased. After guaiacol treatment, the paw swelling of rheumatoid arthritis mice was significantly relieved, the disease score decreased, joint inflammation infiltration and cartilage damage were significantly improved, osteoclast production was inhibited, the number of apoptotic cells at the joints decreased, and the levels of pro-inflammatory factors in the mouse serum were effectively downregulated and the levels of pro-inflammatory repair factors were upregulated.

[0039] 3. For example Figure 11 As shown, guaiacol has good biocompatibility: H&E staining results of the five internal organs showed that there was no significant damage to the five internal organs of mice treated with guaiacol, indicating that guaiacol has biocompatibility at the concentration used in this experiment.

[0040] In conclusion, guaiacol is an important active ingredient that can effectively treat rheumatoid arthritis, and its related applications provide a promising and effective treatment option for rheumatoid arthritis.

Claims

1. Application of guaiacol in the preparation of drugs for treating rheumatoid arthritis.

2. A drug for treating rheumatoid arthritis, characterized in that, Its active ingredient is guaiacol.

3. The medicament for treating rheumatoid arthritis according to claim 2, characterized in that... This includes guaiacol and pharmaceutically acceptable excipients.

4. The medicament for treating rheumatoid arthritis according to claim 3, characterized in that, The drug is in the form of an injection.

5. The medicament for treating rheumatoid arthritis according to claim 4, characterized in that, The injection is an intraperitoneal injection solution.